AG真人官方

Magnite, Inc. (NASDAQ: MGNI) has filed a Form 144 indicating that Chief Executive Officer Michael Barrett intends to sell up to 70,900 common shares around 15 July 2025. The proposed sale, to be executed through Raymond James & Associates, is valued at approximately $1.65 million based on the filing鈥檚 reference price, and represents roughly 0.05 % of the company鈥檚 135.6 million shares outstanding.

The notice also discloses that Barrett acquired the shares earlier in 2025 as restricted stock grants (31,377 shares on 5 Feb; 25,405 on 15 Feb; 14,118 on 15 May). In addition, the CEO sold a total of 375,000 shares during June 2025 for gross proceeds of $7.37 million, underscoring a pattern of recent insider selling.

While the absolute number of shares is small relative to the public float, the consecutive transactions may influence investor sentiment, especially given the seller鈥檚 senior role. The filing contains no indication that the sale is linked to a 10b5-1 trading plan, although it references Rule 10b5-1 compliance language. Investors typically monitor such activity for potential signals about management鈥檚 outlook, liquidity needs, or portfolio diversification.

Key figures:

• Shares to be sold: 70,900
• Aggregate market value: $1,650,160
• Broker: Raymond James & Associates
• Approximate sale date: 15 July 2025
• Shares sold in prior 3 months: 375,000 (gross proceeds $7.37 M)

Given the limited size versus total outstanding shares, the transaction is unlikely to have a material impact on Magnite鈥檚 capitalization but may attract short-term scrutiny regarding insider confidence.

On 11 July 2025, I-MAB (Nasdaq: IMAB) submitted a Form 6-K to notify investors that it has amended its 15 May 2025 prospectus covering the offer and sale of up to US$21 million in American Depositary Shares (ADSs). Each block of ten ADSs represents twenty-three ordinary shares with a par value of US$0.0001. The prospectus is part of the company鈥檚 shelf Registration Statement on Form F-3 (File No. 333-286954).
The filing attaches a Cayman Islands legal opinion from Harney Westwood & Riegels (Exhibit 5.1) together with the corresponding consent (Exhibit 23.1), confirming the validity of the ADSs and underlying ordinary shares. The 6-K states that the information and exhibits are incorporated by reference into the existing Form F-3 and several Form S-8 registration statements covering share-based compensation plans.
No operating or financial results are disclosed. The amendment maintains regulatory compliance and keeps the shelf registration effective, giving I-MAB flexibility to raise up to US$21 million when market conditions permit. While this improves liquidity options, it may also lead to equity dilution for current shareholders if the full amount is issued.

Local Bounti Corporation (LOCL) has filed a Form 144 disclosing a planned disposition of restricted stock under Rule 144 of the Securities Act.

Seller: KEBS Trust
Planned sale: 3,500 common shares
Broker: Morgan Stanley Smith Barney, New York
Approximate sale date: 10 July 2025 (on the NYSE)
Aggregate market value: $9,261.35
Shares outstanding: 10,914,704
This transaction equals roughly 0.03 % of the company鈥檚 outstanding stock, indicating minimal dilution risk.

The shares were originally received as a gift from an affiliate on 28 December 2022. KEBS Trust has already executed several open-market sales in the past three months:

• 09 Jul 2025 鈥� 200 shares 鈥� $602.00
• 22 May 2025 鈥� 1,179 shares 鈥� $2,458.33
• 21 May 2025 鈥� 600 shares 鈥� $1,262.52
• 20 May 2025 鈥� 800 shares 鈥� $1,736.72
• 19 May 2025 鈥� 1,000 shares 鈥� $2,226.60
• 16 May 2025 鈥� 1,421 shares 鈥� $3,326.13

Total prior 3-month sales: 5,200 shares for gross proceeds of about $11,612. The signatory affirms no undisclosed adverse information and acknowledges SEC anti-fraud provisions.

Form 4 filing 鈥� Insider transaction at Gevo (GEVO)

Executive Vice President L. Lynn Smull reported the disposition of 3,928.83 shares of Gevo common stock on 01 Jul 2025 at an average price of $1.33 per share. The shares were held in and sold through the company鈥檚 401(k) plan; a footnote clarifies that 20.63 of those shares were liquidated between 11 Jun 2025 and 07 Jul 2025 to cover plan administrative fees.

After the transaction, Smull鈥檚 indirect 401(k) position stands at 18,098.05 shares. A separate line in the filing indicates 1,171,550 shares of direct ownership, suggesting the officer maintains a substantial equity stake. No derivative securities were reported, and the filing does not reference the use of a Rule 10b5-1 trading plan.

The sale represents a very small fraction of Smull鈥檚 total holdings and is unlikely to have a material effect on Gevo鈥檚 share float or signal a strategic outlook change. The form appears timely and complete, satisfying Section 16 reporting obligations.

On 07/07/2025, FMR LLC 鈥� the parent company of Fidelity Investments 鈥� and its chair & CEO Abigail P. Johnson filed a Schedule 13G disclosing ownership of 5,600,662 common shares of Omada Health, Inc. (OMDA), corresponding to 10.0 % of the outstanding stock as of the event date 06/30/2025.

The filing indicates a passive investment under Rule 13d-1(b). FMR LLC reports sole voting power and sole dispositive power over the entire position, with no shared voting or dispositive authority. Ms. Johnson is deemed a co-reporting beneficial owner because of her control of FMR LLC; she likewise claims sole dispositive power over the same shares.

No purchase price, transaction details, or intent to influence control are provided. The signatories certify that the shares were acquired in the ordinary course of business and not in connection with any control-changing objective or proxy contest. An exhibit lists the subsidiaries through which the securities are held, but those details are not included in the text provided.

Implications for investors:

• A blue-chip institutional investor now holds a double-digit stake, which can enhance market confidence and liquidity.
• Because the filing is on Schedule 13G, FMR signals a passive stance; however, surpassing the 10 % threshold increases its potential influence in future corporate governance matters if it later opts for an active role.
• The concentration of voting rights in a single institution could also become a risk factor should Fidelity decide to trim or exit the position.

The document contains no financial statements, earnings data, or management commentary; it is strictly an ownership disclosure required by SEC rules.

Epsilon Energy Ltd. (EPSN) 鈥� Form 4 insider filing

Chief Executive Officer and Director Jason Stabell reported the automatic issuance of restricted stock that vested on 1 July 2025. Two separate grants became unrestricted:

• 6,098 common shares from a 1 July 2022 award (footnote 1)
• 18,727 common shares from a 1 July 2023 award (footnote 2)

The transactions are coded 鈥淎鈥� (acquisition) and were executed at $0, reflecting share issuance rather than market purchases.

Following these events, Stabell鈥檚 direct holdings increased to 271,671 common shares. He also reports 470,339 shares held indirectly through an LLC, bringing his total disclosed beneficial ownership to roughly 742,010 shares.

No derivative securities were involved, and there were no dispositions. Because the shares stem from previously approved compensation plans, the filing signals continued equity alignment but does not reflect an incremental cash investment by the insider.

The Form 4 filing reports that Chemours Company (CC) director Courtney Mather was awarded 2,292 deferred stock units (DSUs) on 30 June 2025. Each DSU equals one share of common stock and will be settled in the first month after the director leaves the board. The award is recorded at a reference price of $11.45 per unit. After the grant, Mather directly owns 2,292 derivative securities; no sales or additional purchases of common stock were disclosed. Apart from this routine director compensation grant, the filing contains no other material transactions or changes in ownership.

Dillard鈥檚, Inc. (DDS) Form 4 filing dated 07/02/2025 discloses a modest open-market purchase by long-time insider Drue Matheny, Executive Vice President and Director. On 06/30/2025 Matheny acquired 19 Class A common shares at $413.32 each, increasing her direct holding to 403,904 shares. She also continues to hold 36,648 shares through the company retirement plan and 9,821 shares indirectly (7,300 as trustee of the GST Trust and 2,521 held by her spouse). No derivative transactions were reported.

The purchase represents less than 0.005% of her direct ownership and is immaterial to DDS鈥檚 17 million share float, yet any insider buying鈥攑articularly by a senior executive鈥攎ay be interpreted as a confidence signal. There were no sales, option exercises, or 10b5-1 plan indications, and the filing confirms her continuing status as both officer and director.

Dillard鈥檚, Inc. (DDS) Form 4 filing dated 07/02/2025 discloses a modest open-market purchase by long-time insider Drue Matheny, Executive Vice President and Director. On 06/30/2025 Matheny acquired 19 Class A common shares at $413.32 each, increasing her direct holding to 403,904 shares. She also continues to hold 36,648 shares through the company retirement plan and 9,821 shares indirectly (7,300 as trustee of the GST Trust and 2,521 held by her spouse). No derivative transactions were reported.

The purchase represents less than 0.005% of her direct ownership and is immaterial to DDS鈥檚 17 million share float, yet any insider buying鈥攑articularly by a senior executive鈥攎ay be interpreted as a confidence signal. There were no sales, option exercises, or 10b5-1 plan indications, and the filing confirms her continuing status as both officer and director.